Results 101 to 110 of about 8,244 (227)

Cibles des médicaments antithrombotiques [PDF]

, 2006
Pour la quasi-totalité des classes thérapeutiques antithrombotiques actuellement utilisées et à venir, le ciblage a été initialement la conséquence d’une observation et non pas le fruit d’une recherche méthodique scientifique.
Drouet, Ludovic, Ripoll, Laurent
core   +1 more source

Anoikis in cell fate, physiopathology, and therapeutic interventions

MedComm, Volume 5, Issue 10, October 2024.
1. Anoikis is an integrin‐dependent form of apoptosis and can affect cell fate. 2. Anoikis widely exists in the physiological and pathological processes of life. 3. Anoikis‐based regulatory strategies are potential targets for therapeutic intervention.
Jie Mei, Xue‐Yao Jiang, Hui‐Xiang Tian, Ding‐Chao Rong, Jia‐Nan Song, Luozixian Wang, Yuan‐Shen Chen, Raymond C. B. Wong, Cheng‐Xian Guo, Lian‐Sheng Wang, Lei‐Yun Wang, Peng‐Yuan Wang, Ji‐Ye Yin   +12 more
wiley   +1 more source

The impact of antiplatelet and anticoagulant medications on early implant failure following sinus floor augmentation: A retrospective cohort analysis

Clinical Implant Dentistry and Related Research, Volume 26, Issue 5, Page 1046-1055, October 2024.
Abstract Introduction The effect of antiplatelet and anticoagulant medications on the outcomes of sinus floor augmentation remains unclear. Methods This retrospective cohort study analyzed data from electronic medical records of consecutive patients undergoing sinus floor augmentation at a single medical center.
Ehud Jonas, Daya Masri, Gal Avishai, Hiba Masri‐Iraqi, Gavriel Chaushu, Liat Chaushu   +5 more
wiley   +1 more source

Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes [PDF]

, 1999
BACKGROUND: Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac complications in patients with acute coronary syndromes without ST-segment elevation and protect against thrombotic complications associated ...
Akkerhuis, K.M. (Martijn), Boersma, H. (Eric), Califf, R.M. (Robert), Simoons, M.L. (Maarten), Théroux, P. (Pierre), Topol, E.J. (Eric)   +5 more
core  

RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect

Iranian Journal of Biotechnology, 2019
Background Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half ...
Hassan Bardania, S. Shojaosadati, F. Kobarfard, D. Morshedi, F. Aliakbari, M. Tahoori, E. Roshani   +6 more
semanticscholar   +1 more source

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction [PDF]

, 2017
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal is much higher than that of surgical bleeding if they are continued.
Chassot, P.-G, Delabays, A., Spahn, D. R.   +2 more
core  

Investigation of interaction of human platelet membrane components with anticoagulant drugs Abciximab and Eptifibatide

Folia Histochemica et Cytobiologica, 2010
Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications inacute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex ...
Ewa Gorodkiewicz, Anna Sankiewicz, Zbigniew A. Figaszewski   +2 more
doaj  

Platelet Inhibition in Percutaneous Coronary Interventions [PDF]

, 2018
: Mechanical disruption of atherosclerotic plaques at the time of percutaneous coronary intervention (PCI) is a potent stimulus for arterial thrombosis.
Roffi, Marco, Wyss, Christophe
core  

Strategies to inhibit tumour associated integrin receptors: rationale for dual and multi-antagonists [PDF]

, 2014
YesThe integrins are a family of 24 heterodimeric transmembrane cell surface receptors. Involvement in cell attachment to the extracellular matrix, motility, and proliferation identifies integrins as therapeutic targets in cancer and associated ...
Albelda S. M., Amirkhosravi A., Aumailley M., Bandyopadhyay A., Barker P. L., Batt D. G., Bello L., Benfatti F., Bennett J. S., Bianchi-Smiraglia A., Bisanz K., Bochen A., Boys M. L., Bretschi M., Bretschi M., Brooks P. C., Buergy D., Burbridge M. F., Böger C., Calderwood D. A., Calvete J. J., Calvete J. J., Carey C. M., Chen Q., Chico T. J. A., Christoforides C., Chu F. M., Chung K.-H., Cohen S. A., Cox D., Dardik R., Davenport R. J., Davis F. B., De Corte B. L., De S., Dechantsreiter M. A., Dome B., Duan X. P., Engebraaten O., Engleman V. W., Erdreich-Epstein A., Friedlander M., Gasparini G., Gentilucci L., Gomes N., Goodman S. L., Goodman S. L., Goodman S. L., Hailey S., Harms J. F., Heidenreich A., Helen M. Sheldrake, Henderson N. C., Humphries J. D., Ishikawa M., Ishikawa M., Kang I.-C., Kerr J. S., Kim S., Knowles L. M., Kubota D., Kubota D., Kumar C. C., Laurence H. Patterson, Laurens N., Letourneau J. J., Lin E., Liu Y., Lonsdorf A. S., Lucena S. E., Malik G., Marelli U. K., Marinelli L., Marinelli L., Marinelli L., Martin P. L., Martin S., Mas-Moruno C., Mas-Moruno C., Matsuno H., Maubant S., Max R., McCabe N. P., Meerovitch K., Menendez J. A., Minea R., Minea R. O., Mitjans F., Morjen M., Mullamitha S. A., Naber H. P., Nabors L. B., Nadrah K., Nagae M., Oleksowicz L., Osterkamp F., O’Day S., O’Day S. J., Palumbo J. S., Parvani J. G., Pecheur I., Peishoff C. E., Perron-Sierra F., Pfaff M., Pontes-Júnior J., Reinmuth N., Reynolds A. R., Romanov V. I., Ross F. P., Scarborough R. M., Scarborough R. M., Scaringi C., Schaffner F., Schittenhelm J., Schittenhelm J., Schmieder A. H., Schneider J. G., Shannon K. E., Sheldrake H. M., Shih C.-H., Simon K. O., Sloan E. K., Smallheer J. M., Sowmya G., Stachurska A., Steri V., Stragies R., Sung V., Swenson S., Sánchez E. E., The IMPACT-II Investigators., Timar J., Tolomelli A., Topol E. J., Trabocchi A., Trikha M., Trikha M., Trikha M., Trikha M., van den Hoogen C., van der Flier A., van der Horst G., van der Horst G., Vermorken J. B., Vogetseder A., Wan A. M., Wu Y. J., Xiao T., Zhang W., Zhao F., Zhao Y.   +150 more
core   +1 more source

Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)—a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy

Critical Care, 2019
BackgroundPart of the pathophysiology in septic shock is a progressive activation of the endothelium and platelets leading to widespread microvascular injury with capillary leakage, microthrombi and consumption coagulopathy.
R. Berthelsen, S. Ostrowski, M. Bestle, P. I. Johansson   +3 more
semanticscholar   +1 more source